Thermo Fisher Scientific Inc. (TMO) — closed signal from July 24, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on October 22, 2025 — +21.6% at the close.
Predicted vs. what happened
What happened
Reached its target in 88 days.
The thesis — published July 24, 2025
The stock jumped 9.1% after earnings, with three times normal trading, and the company raised its 2025 goals. Core sales grew 3 points faster than expected, and a key supplier also sounded upbeat, showing demand is real. The shares are holding above about $450, and past moves like this often add another 18-22% within three months, which could lift the price toward $560.
Primary drivers
- Strong Q2 and higher 2025 goals hint that drug makers are spending again
- Big post-earnings jump on heavy trading may draw in fast-moving investors
- Another supplier raised its view, confirming demand for lab products
- Healthcare stocks often hold up when markets fall, adding balance
How it played out
TMO: target reached in 88 days
Lyra published TMO at $465.94 on 2025-07-24 with an 18% short-term expected gain and a $548.90 target. The thesis pointed to a 9.1% post-earnings jump, three times normal trading, higher 2025 goals, core sales running 3 points faster than expected, firmer lab-products demand, support near $450, and a defensive healthcare profile.
Inside the window, the stock reached $570.86 on 2025-10-22. That was above the target, with a 22.5% peak gain, and the target was reached in 88 days. It ended at $566.77. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.